A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning / Rikus Knegtering en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 56-61 Título : A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning Tipo de documento: texto impreso Autores: Rikus Knegtering, Autor ; Stynke Castelein, Autor ; Han Bous, Autor Fecha de publicación: 2023 Artículo en la página: pp. 56-61 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Dibenzotiacepinas, Prolactina, Trastornos psicóticos, Fumarato de quetiapina, Risperidona, Esquizofrenia, Disfunciones sexuales, Testosterona. Resumen: To compare sexual functioning in patients treated with quetiapine or risperidone. This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks. Sexual dysfunction was assessed by a semistructured interview, the Antipsychotics and Sexual Functioning Questionnaire (ASFQ), based upon the Utvalg for Kliniske Undersogelser (UKU). Link: ./index.php?lvl=notice_display&id=30979 [artículo] A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning [texto impreso] / Rikus Knegtering, Autor ; Stynke Castelein, Autor ; Han Bous, Autor . - 2023 . - pp. 56-61. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 56-61 Palabras clave: Dibenzotiacepinas, Prolactina, Trastornos psicóticos, Fumarato de quetiapina, Risperidona, Esquizofrenia, Disfunciones sexuales, Testosterona. Resumen: To compare sexual functioning in patients treated with quetiapine or risperidone. This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks. Sexual dysfunction was assessed by a semistructured interview, the Antipsychotics and Sexual Functioning Questionnaire (ASFQ), based upon the Utvalg for Kliniske Undersogelser (UKU). Link: ./index.php?lvl=notice_display&id=30979

---

1 (1 - 1 / 1)